ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome. It is also developing QRX-1011, a single-stranded oligonucleotide for Stargards disease; QRX-704, an oligonucleotide for the treatment of Huntington's disease; and QRX-504 to treat Fuchs' endothelial corneal dystrophy type 3, as well as AT-010, a program for hereditary cerebral hemorrhage with amyloidosis of the Dutch type. The company has a research collaboration agreement with Galapagos N.V. to apply Axiomer, a RNA Editing Technology Platform for various fibrosis targets; and a collaboration agreement with EB Research Partnership and EB Medical Research Foundation to develop QR-313 for patients with dystrophic epidermolysis bullosa. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRQR
CUSIPN/A
Phone31-88-166-7000
Debt
Debt-to-Equity Ratio0.26
Current Ratio4.02
Quick Ratio4.02
Price-To-Earnings
Trailing P/E Ratio-9.92
Forward P/E Ratio-13.95
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.39 per share
Price / Book13.85
Profitability
EPS (Most Recent Fiscal Year)($1.94)
Net Income$-49,320,000.00
Net MarginsN/A
Return on Equity-129.94%
Return on Assets-90.33%
Miscellaneous
Employees130
Outstanding Shares38,550,000
Market Cap$726.61 million
ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions
What is ProQR Therapeutics' stock symbol?
ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."
How were ProQR Therapeutics' earnings last quarter?
ProQR Therapeutics NV (NASDAQ:PRQR) released its quarterly earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.15. View ProQR Therapeutics' Earnings History.
When is ProQR Therapeutics' next earnings date?
What price target have analysts set for PRQR?
3 Wall Street analysts have issued 1 year price objectives for ProQR Therapeutics' stock. Their forecasts range from $9.00 to $35.00. On average, they anticipate ProQR Therapeutics' share price to reach $21.3333 in the next year. This suggests a possible upside of 10.8% from the stock's current price. View Analyst Price Targets for ProQR Therapeutics.
What is the consensus analysts' recommendation for ProQR Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ProQR Therapeutics.
Who are some of ProQR Therapeutics' key competitors?
Some companies that are related to ProQR Therapeutics include ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), TESARO (TSRO), Amicus Therapeutics (FOLD), Heron Therapeutics (HRTX), Mallinckrodt (MNK), Myokardia (MYOK), Opko Health (OPK), The Medicines (MDCO), Arena Pharmaceuticals (ARNA), Global Blood Therapeutics (GBT), PTC Therapeutics (PTCT) and Pacira Pharmaceuticals (PCRX).
Who are ProQR Therapeutics' key executives?
ProQR Therapeutics' management team includes the folowing people:
- Mr. Daniel A. de Boer, CEO & Member of Management Board (Age 35)
- Mr. Rene K. Beukema, Chief Corp. Devel. Officer, Gen. Counsel, Corp. Sec. & Member-Management Board (Age 54)
- Ms. Smital Shah, Chief Financial Officer (Age 42)
- Mr. Joost Clement, Director of HR
- Mr. Bart Klein, Sr. VP of Intellectual Property
Who are ProQR Therapeutics' major shareholders?
ProQR Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Street Advisors Inc. NC (0.16%) and Essex Investment Management Co. LLC (0.08%).
Which institutional investors are selling ProQR Therapeutics stock?
PRQR stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC and Franklin Street Advisors Inc. NC.
How do I buy shares of ProQR Therapeutics?
Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ProQR Therapeutics' stock price today?
One share of PRQR stock can currently be purchased for approximately $19.25.
How big of a company is ProQR Therapeutics?
ProQR Therapeutics has a market capitalization of $726.61 million. The biopharmaceutical company earns $-49,320,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. ProQR Therapeutics employs 130 workers across the globe.
What is ProQR Therapeutics' official website?
How can I contact ProQR Therapeutics?
ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at 31-88-166-7000 or via email at [email protected]
MarketBeat Community Rating for ProQR Therapeutics (NASDAQ PRQR)
MarketBeat's community ratings are surveys of what our community members think about ProQR Therapeutics and other stocks. Vote "Outperform" if you believe PRQR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRQR will underperform the S&P 500 over the long term. You may vote once every thirty days.
